Endomysial antibodies or anti‐tissue transglutaminase type 2 IgA antibodies as a confirmatory test in children with celiac disease

Amir Ben‐Tov,Tomer Achler,Rochelle Fayngor,Raanan Shamir,Lia Supino,Yael Weintraub,Anat Yerushalmy‐Feler,Shlomi Cohen
DOI: https://doi.org/10.1002/jpn3.12383
2024-10-14
Journal of Pediatric Gastroenterology and Nutrition
Abstract:The no‐biopsy approach to diagnose celiac disease (CD), introduced in the 2012 European Society for Gastroenterology and Hepatology and Nutrition guidelines, requires an anti‐endomysial antibody (EMA) confirmatory serology test following a high‐positive immunoglobulin A anti‐tissue transglutaminase‐2 (anti‐TG2) antibody ≥10 times the upper limit of normal (ULN). The aim of this retrospective study is to compare EMA positivity and high‐positive anti‐TG2 in patients who had their confirmatory test within two month of their first high‐positive anti‐TG2 test. Among 933 patients who had high‐positive anti‐TG2 serology more than 10 times the ULN in their first sample, all had both high‐positive anti‐TG2 and positive EMA, most of them with very high EMA titers (99.6%) in their confirmatory test. In conclusion, we suggest that a repeated anti‐TG2 test can replace the EMA test as the confirmatory serology test for the confirmation of the diagnosis of CD in the no‐biopsy approach.
pediatrics,gastroenterology & hepatology,nutrition & dietetics
What problem does this paper attempt to address?